Background Annually, 4% of the global population undergoes non-cardiac surgery, with 30% of those patients having at least ...

Catching you up on the most notable product releases from the world's biggest consumer electronics show: CES 2026.

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...